Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03340610 · ClinicalTrials.gov registry record · Phase 4
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
A Phase 4 study of Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03340610: Completed Phase 4 study of Diabetic Macular Edema, sponsored by Southeast Retina Center, Georgia.
NCT03340610 is a Phase 4 study of Diabetic Macular Edema that has completed, run by Southeast Retina Center, Georgia. The registered enrollment target is 30 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03340610, a Phase 4 study of Diabetic Macular Edema, has completed, sponsored by Southeast Retina Center, Georgia.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
Primary Outcome
Reduction in macular edema measured as * Proportion of eyes with baseline SD OCT CST \>350 um demonstrating \>15% reduction at week 52 from baseline * Proportion of eyes that demonstrate SD OCT CST \<305um (males) and \<290 um (females) at week 52 from baseline
Conditions Studied
Interventions
- DRUG Alflibercept
Study Locations (1)
Georgia
- Southeast Retina Center - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-12-12 |
| Phase | Phase 4 |
What the finished NCT03340610 record still lists
NCT03340610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Alflibercept is the first listed.
NCT03340610 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT03340610 about?
NCT03340610 is a clinical study titled "IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab". This is a phase 4 prospective, nonrandomized, open label, interventional clinical trial. Study eyes will receive 5 required initial monthly Intravitreal Aflibercept (IAI) doses of 2 mg followed by 2q8 IAI for a total of 52 weeks; only one study eye from each patient will be enrolled.
What is the current status of trial NCT03340610?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2015-06. Estimated completion is 2018-12-12.
What conditions does trial NCT03340610 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT03340610?
The interventions under investigation include: Alflibercept (DRUG).
Who is sponsoring clinical trial NCT03340610?
This trial is sponsored by Southeast Retina Center, Georgia, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03340610 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03340610's enrollment target sits among peer trials
30 45th of 63 higher than 18 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
COMPLETED · Phase 4
-
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia